New West Dental Lab Introduces EndSnorZ\u2122 Sleep Appliance
New Mandibular Advancement Device Provides Dentists with an Innovative 3D-Printed Option to Treat Patients with Sleep Apnea

New West Dental Lab, a full-service dental laboratory that has been serving dentists nationally for over 40 years, has announced a new addition to its family of mandibular advancement devices (MADs), the EndSnorZ™ Sleep Appliance. Available exclusively from New West, the new appliance is a patient-specific device that is adjustable in 0.5 mm increments across a 10 mm range to treat snoring and obstructive sleep apnea (OSA). Dentists who trust New West with their crown & bridge restorations will find the EndSnorZ to be a reliable and precise 3D-printed appliance that fits well with the high-quality standards that the dental treatment of snoring and sleep apnea demands.

"I'm pleased to announce the availability of the EndSnorZ Sleep Appliance," said New West General Manager Hollie Taylor, CDT. "This device reflects our commitment to collaborating with our dentist customers and innovating the tools and techniques that help deliver the highest possible level of care for dental patients. The new EndSnorZ appliance builds on the latest cutting-edge CAD/CAM processes as well as 3D printing technologies to deliver an exceptional dental experience for both the clinician and patient."

The dental treatment of snoring and sleep apnea requires a trained dentist to position the jaw during sleep so that the tissues, muscles and ligaments of the upper airway have slight tension. This stops the vibration and partial airway collapse that creates the snoring sound. It also treats OSA by defending the airway from complete collapse.

All MADs, including the EndSnorZ, have a similar method of action. Upper and lower nightguards of the appliance have the same fit, form and function that dentists who treat snoring and sleep apnea are familiar with. The differences are in the orientation and material for the connector arms. EndSnorZ connector arms work through traction, gently pulling the jaw into position. This traction also tends to hold the mouth closed and prevents the jaw from collapsing during sleep, which would otherwise obstruct the airway. The EndSnorZ appliance encourages closed-mouth, quiet nasal breathing, increases patient comfort and provides a more restful sleep.

"Success in the practice of dental sleep medicine requires durable materials and precise, predictable fit, form and function," said Taylor. "The EndSnorZ appliance fills this requirement. Furthermore, it is affordably priced at $247 and it includes our standard two-year MAD warranty. This device provides many benefits for dentists interested in growing their practice with oral appliance therapy."

In its four decades of serving dentists across the country, New West Dental Lab has worked very closely with dental teams and vendor groups to provide an elevated patient experience. To learn more or to receive information about the appliance call 800-321-1614 or visit newwestlab.com/sleep.

Grow: The Clinical Advancement Platform

StaffGarden, the leader in software development supporting professional advancement programs such as clinical ladder programs that help nurses advance in their careers, is announcing a year-long partnership with the faith-based healthcare system AdventHealth. AdventHealth has more than 50 hospitals and hundreds of care sites in almost a dozen states, with 6.8 million patient interactions annually.

The clinical ladder is a structured system, traditionally on paper, to support nurses' career advancement while remaining in their current clinical setting, providing direct patient care.

Digitizing the clinical ladder in healthcare systems to promote nurse engagement has been overlooked in the industry. Grow, from StaffGarden, has stepped in and given nurses a better way to advance their careers by providing software that organizes materials in one centralized hub while tracking engagement. StaffGarden provides innovative technology solutions to over 800 facilities nationwide and will expand further in 2023.

"AdventHealth is an excellent partner to work with," Brian Card, StaffGarden's Vice President, said. "It's truly impressive to see our product impact the healthcare industry, helping nurses progress in their careers and assisting health systems with engagement and retention at such a critical time."

AdventHealth chose the StaffGarden Grow platform in early 2022 to launch its Professional Excellence Program across the system throughout 2022 and 2023. AdventHealth began with its direct care nurses and later expanded to a second program for assistant nurse managers.

"StaffGarden's platform has been integral to the successful launch of our national Nursing Professional Excellence Program. It supports the professional development needs of our nursing workforce. The platform is intuitive and makes it easy for our nurses to input the documentation supporting their work," said Trish Celano, Chief Nurse Executive for AdventHealth. "Also, the review and approval process for our nurse leaders is efficient." 

About StaffGarden

StaffGarden is the leading digital healthcare company in software development supporting Clinical Ladder, Competency Assessments, Peer Reviews, Magnet Tracking, and Portfolio Management in healthcare systems. StaffGarden is revolutionizing the way nurses track, share and manage their nursing careers. With seven years of experience, we are poised to take your clinical ladder to the next level. To learn more about StaffGarden, check us out on LinkedIn or at StaffGarden.com.

About AdventHealth

With a sacred mission of Extending the Healing Ministry of Christ, AdventHealth is a connected system of care for every stage of life and health. More than 80,000 skilled and compassionate caregivers in physician practices, hospitals, outpatient clinics, skilled nursing facilities, home health agencies, and hospice centers provide individualized, wholistic care. A shared vision, common values, focus on whole-person health, and commitment to making communities healthier unify the system's more than 50 hospital campuses and hundreds of care sites in diverse markets throughout almost a dozen states. For more information about AdventHealth, visit AdventHealth.com/news.

A person holding a Senzo Amplified Lateral Flow test.

Senzo, a life sciences company developing high accuracy, low-cost point-of-care diagnostic technologies, today announced a $1.9 million investment led by existing investors BioAdvance and Wellness Coaches.

The funding follows recent blinded studies by UCL and LateralDx, confirming that the Senzo Amplified Lateral Flow test had 98% accuracy in comparison to PCR in correctly identifying COVID-19 virus in samples, even at very low viral loads above 30 Ct. These studies, combined with an earlier study by Sheffield University, demonstrate the high performance of the Senzo Amplified Lateral Flow (ALF) platform. ALF is the only platform that combines the speed and low cost of lateral flow tests with the accuracy of PCR tests.

The investment will be used to complete validation, execute clinical trials, secure FDA EUA authorization, and scale manufacturing for the ALF COVID-19 test, as well as to advance R&D for new Flu A/B, RSV, Tuberculosis, HIV, Hepatitis-C, and Strep tests.

"This funding further indicates the interest and excitement investors have in the ALF platform, and is another important step in bringing our technology to market. Whether for COVID-19, TB, Flu, or a range of other diseases, there are patients in desperate need of better at-home, rapid-test diagnostics, and a huge market needing our tests. This investment will help us bring this innovative technology to market even faster," said Jeremy Stackawitz, CEO of Senzo Health.

Senzo plans to complete ALF COVID-19 clinical trials and secure FDA EUA regulatory approval in 1H 2023, with tests commercially available in the 2H 2023.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies, with a focus on enhanced sensitivity, to create mobile, point-of-care and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms.

About BioAdvance:

BioAdvance is an early-stage life sciences fund with a focus in the mid-Atlantic region, investing up to $1.5 million initially and up to $5 million over the lifetime of companies with the potential to significantly improve human health. www.bioadvance.com.

About Wellness Coaches:

Wellness Coaches is one of the largest and most-experienced tech-enabled wellness, nutrition, clinical, and injury prevention service providers, utilizing both onsite and virtual expertise to help communities and organizations increase engagement, improve population health, mitigate safety risks, and reduce healthcare and workers' compensation costs. www.wcusa.com. 

For more information, visit https://www.senzo.com.

Press Contact:
Alex Mohacs
[email protected]

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic. Recently, Gb Sciences received positive preclinical results supporting the efficacy of its proprietary kava-based formulas designed for the treatment of anxiety, which were obtained as a part of its ongoing preclinical study of kava-inspired formulations for the treatment of anxiety or depression. Gb Sciences' psychotropic, kava-inspired formulas enhance mood, but they do not have potentially unwanted psychedelic side effects.

"While kava-based formulations are not well publicized, we believe they hold significant potential for the treatment of anxiety and depression without the hallucinogenic effects of more recently popularized treatments based on classical psychedelic molecules," explained Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. "Gb Sciences has leveraged its patent-pending platform, PhAROS or Phytomedical Analytics for Research Optimization at Scale, to identify novel drug candidates based on potentially synergistic combinations of kava plant compounds designed to address these serious mental health disorders."

Approximately 300 million people in the world suffer from anxiety and depression, while effective clinical treatments are still limited globally. Recently, psychedelic treatments have received significant attention based on their potential to treat anxiety and depression, among other mental health challenges and addictions. In fact, several publicly traded companies valued at a billion dollars each have emerged as leaders within the psychedelic development space bolstered by preliminary published psychedelic research. While these novel psychedelic treatments may be a good option for some patients with anxiety or depression, there are significant limitations that may prevent them from becoming widely adopted, including their negative stigma, the lack of scientific research defining the pros and cons of these treatments, and the fact that the psychedelic side effects may be unwanted by many potential patients and their employers.

Gb Sciences has leveraged its AI-enabled drug discovery technology to develop kava plant-inspired treatments for anxiety and depression that are designed to enhance mood but are non-psychedelic. Gb Sciences has recently received positive preclinical results supporting the efficacy of its proprietary kava-based formulas designed for the treatment of anxiety, and Gb Sciences has additional kava-inspired formulations being tested for the treatment of anxiety and depression at the National Research Council of Canada ("NRC") through GbS' Canadian subsidiary, GbS Global Biopharma, Inc.

Learn more by visiting www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also recently received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes," and words of similar import may identify forward-looking statements. These statements are not historical facts but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.